Nvidia brings drug-hunting AI to AWS
Nvidia just launched its generative AI drug discovery platform, BioNeMo, on AWS via Amazon SageMaker and ParallelCluster. Researchers can scale digital biology models like ESM-2 across up to 512 H100 GPUs, cutting training runs from a month down to just a few days. Why it matters: Biotech teams can now fine-tune foundation models directly on their proprietary lab data using standard AWS cloud infrastructure.